Table 1 Clinical characteristics, treatment and outcomes of
RA-UIP patients |
Table 1 Clinical characteristics, treatment
and outcomes of RA-UIP patients |
Table 1 Clinical
characteristics, treatment and outcomes of RA-UIP patients |
Table 1 Clinical characteristics, treatment and outcomes of
RA-UIP patients |
Table 1 Clinical characteristics, treatment
and outcomes of RA-UIP patients |
Table 1 Clinical
characteristics, treatment and outcomes of RA-UIP patients |
Table 1 Clinical characteristics, treatment and outcomes of
RA-UIP patients |
Table 1 Clinical characteristics, treatment
and outcomes of RA-UIP patients |
Table 1 Clinical
characteristics, treatment and outcomes of RA-UIP patients |
Table 1 Clinical characteristics, treatment and outcomes of
RA-UIP patients |
Table 1 Clinical characteristics, treatment
and outcomes of RA-UIP patients |
Table 1 Clinical
characteristics, treatment and outcomes of RA-UIP patients |
Table 1 Clinical characteristics, treatment and outcomes of
RA-UIP patients |
Table 1 Clinical characteristics, treatment
and outcomes of RA-UIP patients |
Table 1 Clinical
characteristics, treatment and outcomes of RA-UIP
patients |
Case 2
|
F/73
|
4
|
No
|
transient ischemic attack
|
Arthritis+
UIP
|
14
|
NSAIDS,
Herb
|
Pred15+
Tof+IGU
|
Pred5+Tof+
IGU/4
|
Arthritis+UIP/
Relieved
|
Pred5+Tof+
IGU/1,
Pred5+IGU/3
|
Arthritis+UIP/
Aggravated
|
Pred5+Tof+
IGU/2,
Pred5/4
|
Arthritis+UIP/
Aggravated
|